Jun 03, 2020
New First-in-Class Phase 3 TREMFYA® (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
Jun 03, 2020
EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
Jun 01, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
May 27, 2020
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
Apr 24, 2020
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Apr 15, 2020
Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheumatology and Therapy
Apr 06, 2020
The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic Arthritis
Mar 30, 2020
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Mar 09, 2020
The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026
Mar 06, 2020
Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028
Mar 04, 2020
Mallinckrodt Announces Publication of New Data on Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Dermatomyositis/Polymyositis Published in Open Access Rheumatology: Research and Reviews
Feb 05, 2020
RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Feb 04, 2020
Psoriatic Arthritis Treatment Market to Reach $13.74 Bn, Globally, by 2026 at 7.2% CAGR, Says Allied Market Research
Feb 03, 2020
Global Arthritis Therapeutics Market to Grow at Over 6% Annually to Reach USD 72 Billion Valuation by 2027: Transparency Market Research
Nov 21, 2019
Amgen Completes Acquisition Of Otezla® (apremilast)
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Nov 12, 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
Nov 11, 2019
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Nov 08, 2019
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
Nov 07, 2019
Global Psoriasis Drugs Market Report 2019: Market was Valued at $30.13 Billion in 2018 and is Expected to Grow to $46.57 Billion